We also observed that reduced RPL22 expression was associated with lower hemoglobin (Hb) levels, a marker of MDS severity (Figure 1C).23 Since MDS often progresses to AML, we evaluated RPL22 expression in bulk tumor from patients with AML using data obtained from the Beat AML consortium and The Cancer Genome Atlas (TCGA).24 Strikingly, RPL22 expression was significantly decreased among most patients with AML compared to healthy controls (Figures 1D and S1A). The gene discussed is RPL22; the disease is myelodysplastic syndrome.